Literature DB >> 18692053

Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors.

Abby Siegel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18692053      PMCID： PMC2580074          DOI： 10.1053/j.gastro.2008.07.036

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  22 in total

1.  Trastuzumab in the treatment of breast cancer.

Authors:  Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

2.  Expression of c-kit protooncogene in human hepatocellular carcinoma.

Authors:  Chih-Yuan Chung; Kun-Tu Yeh; Nicholas C Hsu; Julia Huei-Mei Chang; Jen-Tsun Lin; Huey-Ching Horng; Cheng-Shyong Chang
Journal:  Cancer Lett       Date:  2005-01-20       Impact factor: 8.679

3.  Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo.

Authors:  Rebecca Lim; Belinda Knight; Keyur Patel; John G McHutchison; George C Yeoh; John K Olynyk
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

4.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

Authors:  Ju-Seog Lee; Jeonghoon Heo; Louis Libbrecht; In-Sun Chu; Pal Kaposi-Novak; Diego F Calvisi; Arsen Mikaelyan; Lewis R Roberts; Anthony J Demetris; Zongtang Sun; Frederik Nevens; Tania Roskams; Snorri S Thorgeirsson
Journal:  Nat Med       Date:  2006-03-12       Impact factor: 53.440

Review 5.  Opportunities for targeted therapies in hepatocellular carcinoma.

Authors:  Melanie B Thomas; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

Review 6.  Hepatocellular carcinoma: recent trends in the United States.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.

Authors:  F Eckel; S von Delius; M Mayr; M Dobritz; F Fend; C Hosius; E Schleyer; E Schulte-Frohlinde; R M Schmid; C Lersch
Journal:  Oncology       Date:  2005-11-24       Impact factor: 2.935

8.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Authors:  Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

9.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

Authors:  Gabriele Bergers; Steven Song; Nicole Meyer-Morse; Emily Bergsland; Douglas Hanahan
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

10.  C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.

Authors:  Belinda Knight; Janina E E Tirnitz-Parker; John K Olynyk
Journal:  Gastroenterology       Date:  2008-06-03       Impact factor: 22.682
View more
  1 in total

Review 1.  Targeted therapy for hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.